After UK, US FDA approves 2 gene therapies to treat sickle-cell patients
The US Food and Drug Administration on Saturday approved two cell-based gene therapies -- Casgevy and Lyfgenia -- to sickle cell disease (SCD) patients 12 years and older.
This comes weeks after the UK approved the gene therapy, a world…